Analysis of KRAS Mutations in Gastrointestinal Tract Adenocarcinomas Reveals Site-Specific Mutational Signatures

被引:1
|
作者
Wang, Linyuan [1 ]
Saeedi, Bejan J. [2 ]
Mahdi, Zaid [3 ]
Krasinskas, Alyssa [3 ]
Robinson, Brian [3 ]
机构
[1] Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med Univ, Calgary, AB, Canada
[2] Univ Sch Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA
[3] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA
关键词
adenocarcinoma; gastrointestinal; KRAS; molecular pathology; mutational signature; PANCREATIC ADENOCARCINOMA; CANCER; SMAD4; ESOPHAGEAL; GENOME; GENE;
D O I
10.1016/j.modpat.2022.100014
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Adenocarcinomas of the luminal gastrointestinal tract and pancreatobiliary system often show histologic and immunohistochemical overlap, making delineation of the primary site in a metastatic setting difficult. Previous studies have shown that site-specific missense mutations in the oncogene KRAS could be used in conjunction with immunohistochemistry to differentiate metastatic pancreatic adenocarci-noma from primary lung adenocarcinoma. In this study, we assessed the patterning of KRAS mutations across sites in the gastrointestinal and pancreatobiliary system. By integrating sequencing data from 44 separate studies, we assessed 2523 KRAS mutations in 7382 distinct cases of adenocarcinoma, including those from the esophagus, stomach, ampulla, biliary system, pancreas, and colon. We found that gastrointestinal adenocarcinomas demonstrate a marked regional variation in the frequency of KRAS mutations, with the most frequent KRAS mutation observed in pancreatic adenocarcinoma (up to 94.9%), whereas the frequency is much lower in adenocarcinomas from the esophagus and stomach (5.4% and 8.7%, respectively). Intriguingly, the pattern of missense mutations showed site specificity as well, with c.35G>T (p.G12V) and c.34G>C (p.G12R) mutations enriched in pancreatic primaries and codon 13 and nonecodon 12/13 alterations enriched in gastric primaries (specificity of 98.9% and 93.2%, respectively, with a negative predictive value of 93.6% and 92.93% against pancreatic adenocarcinoma). Furthermore, we found that esophageal and gastric adenocarcinomas show an enrichment in transitional mutations, whereas other sites showed an equal distribution. Importantly, the examination of a validation cohort from our own institution revealed similar trends. These findings indicate that, in addition to providing therapeutic and diagnostic information, KRAS mutational analysis may also prove useful in delineating the site of origin in gastrointestinal adenocarcinomas that share morphologic and immunohistochemical overlap. Moreover, transitional mutations are more frequent in esophageal and gastric adenocarcinomas, reiterating the role of chronic inflammation in the pathogenesis of foregut adenocarcinomas.(c) 2022 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Analysis of KRAS Mutational Profiles in the Gastrointestinal Tract Reveals Site-specific Alterations that Can Help Distinguish Pancreatobiliary and Upper Gastrointestinal Primaries
    Wang, Linyuan
    Mahdi, Zaid
    Krasinskas, Alyssa
    Robinson, Brian
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 487 - 488
  • [2] Analysis of KRAS Mutational Profiles in the Gastrointestinal Tract Reveals Site-specific Alterations that Can Help Distinguish Pancreatobiliary and Upper Gastrointestinal Primaries
    Wang, Linyuan
    Mahdi, Zaid
    Krasinskas, Alyssa
    Robinson, Brian
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 487 - 488
  • [3] Site-specific drug delivery in the gastrointestinal tract
    Wilding, I
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2000, 17 (06): : 557 - 620
  • [4] Site-specific analysis of mutational effects proteins
    Di Cera, E
    ADVANCES IN PROTEIN CHEMISTRY, VOL 51, 1998, 51 : 59 - 119
  • [5] Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors
    Suehara, Yoshiyuki
    Kikuta, Kazutaka
    Nakayama, Robert
    Fujii, Kiyonaga
    Ichikawa, Hitoshi
    Shibata, Tatsuhiro
    Seki, Kunihiko
    Hasegawa, Tadashi
    Gotoh, Masahiro
    Tochigi, Naobumi
    Shimoda, Tadakazu
    Shimada, Yasuhiro
    Sano, Takeshi
    Beppu, Yasuo
    Kurosawa, Hisashi
    Hirohashi, Setsuo
    Kawai, Akira
    Kondo, Tadashi
    PROTEOMICS CLINICAL APPLICATIONS, 2009, 3 (05) : 584 - 596
  • [6] Prognostic value of specific KRAS mutations in lung adenocarcinomas
    Siegfried, JM
    Gillespie, AT
    Mera, R
    Casey, TJ
    Keohavong, P
    Testa, JR
    Hunt, JD
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1997, 6 (10) : 841 - 847
  • [7] Site-Specific Polymer Conjugation Stabilizes Therapeutic Enzymes in the Gastrointestinal Tract
    Schulz, Jessica D.
    Patt, Melanie
    Basler, Sophie
    Kries, Hajo
    Hilvert, Donald
    Gauthier, Marc A.
    Leroux, Jean-Christophe
    ADVANCED MATERIALS, 2016, 28 (07) : 1455 - 1460
  • [8] Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
    Kim, Mi-Jung
    Lee, Hye Seung
    Kim, Jee Hyun
    Kim, Yu Jung
    Kwon, Ji Hyun
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Park, Kyoung Un
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Jae-Sung
    Lee, Jong Seok
    Lee, Keun-Wook
    BMC CANCER, 2012, 12
  • [9] Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
    Mi-Jung Kim
    Hye Seung Lee
    Jee Hyun Kim
    Yu Jung Kim
    Ji Hyun Kwon
    Jeong-Ok Lee
    Soo-Mee Bang
    Kyoung Un Park
    Duck-Woo Kim
    Sung-Bum Kang
    Jae-Sung Kim
    Jong Seok Lee
    Keun-Wook Lee
    BMC Cancer, 12
  • [10] Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder
    Szarvas, Tibor
    Reis, Henning
    JOURNAL OF PATHOLOGY, 2024, 263 (4-5): : 400 - 402